Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
Evan Stein, MD, PhD
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Causal relationship between elevated Lp(a) levels and CKD risk
Anne Langsted, MD, PhD
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
Pasquale Perrone-Filardi, MD, PhD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.